The Systemic Sclerosis pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- Agency -.
Systemic Sclerosis Pipeline Review, H2 2017 report is complete research and development history and latest news and press releases.
Key players of H2 Systemic Sclerosis Pipeline by Allergan Plc, AnaMar AB, Angion Biomedica Corp, arGentis Pharmaceuticals LLC, Bayer AG, Biogen Inc, BLR Bio LLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Covis Pharmaceuticals Inc, CSL Ltd, Cumberland Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Fibrocell Science Inc, GenKyoTex SA, Gilead Sciences Inc, GlaxoSmithKline Plc, iBio Inc, Inventiva, Leadiant Biosciences Inc, MedImmune LLC, Patagonia Pharmaceuticals LLC, PDX Pharmaceuticals LLC, Peptinov SAS, ProMetic Life Sciences Inc, Ribomic Inc, Samumed LLC, Sanofi, Seattle Genetics Inc, Stemline Therapeutics Inc, Stratatech Corp, Vicore Pharma AB, viDA Therapeutics Inc, VivaCell Biotechnology Espana SL
Get Systemic Sclerosis - Pipeline Review, H2 2017@ www.reportsnreports.com/contacts/discount.aspx?name=1132622
Systemic Sclerosis (Scleroderma) - Drug Profiles
Abatacept, acALY-18, ambrisentan, anabasum, ANG-3070, ARG-201, belimumab, brentuximab vedotin, C-1889, C-21, C-82, CM-101, dimethyl fumarate DR, elapegademase, factor XIII (human), FCX-013, GKT-831, GSK-2330811, IBIOCFB-03, ifetroban sodium, IVA-337, M-10, MEDI-7734, miRNA-29, nintedanib, nitroglycerin, onabotulinumtoxinA, PAT-048, PATS-03, PBI-4050, PBI-4425, PDX-002, PPV-06, RBM-006, riociguat, rituximab biosimilar more
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation.
- Agency -.
Access Complete Report On Systemic Sclerosis Pipeline (Scleroderma) Review, H2 2017: www.reportsnreports.com/purchase.aspx?name=1132622
Systemic Sclerosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Sclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 2, 2 and 1 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis. The report reviews pipeline therapeutics for Systemic Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved Systemic Sclerosis therapeutics and enlists all their major and minor projects. The report assesses Systemic Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis
List of Figures
Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.
For more information: